CU20080115A7 - Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa - Google Patents

Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa

Info

Publication number
CU20080115A7
CU20080115A7 CU20080115A CU20080115A CU20080115A7 CU 20080115 A7 CU20080115 A7 CU 20080115A7 CU 20080115 A CU20080115 A CU 20080115A CU 20080115 A CU20080115 A CU 20080115A CU 20080115 A7 CU20080115 A7 CU 20080115A7
Authority
CU
Cuba
Prior art keywords
pirrolopirazoles
carbonilamino
quinasa
powerful inhibitors
formula
Prior art date
Application number
CU20080115A
Other languages
English (en)
Other versions
CU23751B7 (es
Inventor
Anle Yang
Jayashree Girish Tikhe
Haitao Li
Mary Catherine Johnson
Liming Dong
Junhu Zhang
Chuangxing Guo
Yufeng Hong
Indrawan James Mcalpine
Susan Elizabeth Kephart
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CU20080115A7 publication Critical patent/CU20080115A7/es
Publication of CU23751B7 publication Critical patent/CU23751B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan compuestos de carbonilamino pirrolopirazol de fórmula I, composiciones que incluyen estos compuestos y sus procedimientos de uso. Los compuestos preferidos de fórmula I tienen actividad como inhibidores de proteína quinasa, incluyendo como inhibidores de PAK4. ESPACIO PARA FÓRMULA
CU20080115A 2005-12-21 2008-06-19 Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa CU23751B7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08

Publications (2)

Publication Number Publication Date
CU20080115A7 true CU20080115A7 (es) 2010-08-30
CU23751B7 CU23751B7 (es) 2012-01-31

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20080115A CU23751B7 (es) 2005-12-21 2008-06-19 Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa

Country Status (26)

Country Link
US (1) US7884117B2 (es)
EP (1) EP1979356B1 (es)
JP (1) JP4635089B2 (es)
KR (1) KR101029167B1 (es)
AP (1) AP2369A (es)
AU (1) AU2006327866B2 (es)
BR (1) BRPI0620354A2 (es)
CA (1) CA2634381C (es)
CR (1) CR10094A (es)
CU (1) CU23751B7 (es)
DK (1) DK1979356T3 (es)
EA (1) EA015513B1 (es)
EC (1) ECSP088558A (es)
ES (1) ES2435405T3 (es)
GE (1) GEP20104974B (es)
HR (1) HRP20130976T1 (es)
IL (1) IL191776A (es)
MA (1) MA30076B1 (es)
ME (1) MEP0808A (es)
MY (1) MY151455A (es)
NO (1) NO20082482L (es)
NZ (1) NZ568692A (es)
PL (1) PL1979356T3 (es)
PT (1) PT1979356E (es)
RS (2) RS20080281A (es)
WO (1) WO2007072153A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
RU2572826C2 (ru) 2008-12-02 2016-01-20 Чиралджен, Лтд. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP5868324B2 (ja) * 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
KR20130121122A (ko) 2010-11-17 2013-11-05 에프. 호프만-라 로슈 아게 종양의 치료 방법
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
AU2012284265B2 (en) 2011-07-19 2017-08-17 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
KR20140135198A (ko) 2012-03-16 2014-11-25 에프. 호프만-라 로슈 아게 Pak1 억제제로 흑색종을 치료하는 방법
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JP6690543B2 (ja) 2014-10-31 2020-04-28 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物
AU2015371251B2 (en) * 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1246645A1 (zh) 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2989519C (en) 2015-06-15 2023-09-26 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
US12304913B2 (en) 2018-11-14 2025-05-20 Ube Industries, Ltd. Dihydropyrrolopyrazole derivative
JP7660063B2 (ja) * 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2349762T3 (es) 2000-08-10 2011-01-11 Pfizer Italia S.R.L. Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden.
JP2005537290A (ja) 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
ATE546452T1 (de) * 2003-09-23 2012-03-15 Vertex Pharma Pyrazolopyrrolderivate als proteinkinaseinhibitoren
AU2005323797B2 (en) * 2005-01-10 2009-07-09 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors

Also Published As

Publication number Publication date
AU2006327866B2 (en) 2012-06-14
ES2435405T3 (es) 2013-12-19
HK1128290A1 (en) 2009-10-23
CU23751B7 (es) 2012-01-31
WO2007072153A2 (en) 2007-06-28
EP1979356B1 (en) 2013-09-18
JP4635089B2 (ja) 2011-02-16
GEP20104974B (en) 2010-04-26
AU2006327866A1 (en) 2007-06-28
CA2634381C (en) 2011-03-08
IL191776A (en) 2013-03-24
JP2009520805A (ja) 2009-05-28
MY151455A (en) 2014-05-30
ME00006B (me) 2010-02-10
IL191776A0 (en) 2008-12-29
ECSP088558A (es) 2008-07-30
RS20080281A (sr) 2009-09-08
MEP0808A (xx) 2010-02-10
NO20082482L (no) 2008-07-02
KR20080080567A (ko) 2008-09-04
RS53029B (sr) 2014-04-30
US7884117B2 (en) 2011-02-08
AP2008004506A0 (en) 2008-06-30
WO2007072153A3 (en) 2007-10-25
PT1979356E (pt) 2013-11-21
AP2369A (en) 2012-02-29
CA2634381A1 (en) 2007-06-28
MA30076B1 (fr) 2008-12-01
EA015513B1 (ru) 2011-08-30
WO2007072153A8 (en) 2008-08-14
CR10094A (es) 2008-08-01
EP1979356A2 (en) 2008-10-15
EA200801291A1 (ru) 2008-12-30
KR101029167B1 (ko) 2011-04-12
BRPI0620354A2 (pt) 2011-11-08
US20090318440A1 (en) 2009-12-24
DK1979356T3 (da) 2013-11-18
NZ568692A (en) 2011-07-29
HRP20130976T1 (hr) 2013-11-22
PL1979356T3 (pl) 2014-01-31

Similar Documents

Publication Publication Date Title
CU23751B7 (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
CU23778B7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
GT200600035A (es) Aminopiridinas como inhibidores de beta-secretasa
UY30748A1 (es) Compuesto0s novedosos
MX382352B (es) Compuestos de heteroarilo y usos de los mismos.
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
CR9786A (es) Compuestos de bencimidazol-tiofeno
GT200900027A (es) Compuestos organicos
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
EA201070278A1 (ru) Ингибиторы гамма-секретазы
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
NO20071127L (no) Triazoloftalaziner
CR8986A (es) Isoxazoles sustituidos como fungicidas
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
GT200600117A (es) Nuevos compuestos farmaceuticos
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
GT200600253A (es) Aminopirimidinas como moduladores de quinasas
UY30801A1 (es) Compuestos calciliticos
EA200901504A1 (ru) Производные пиразолона, как ингибиторы pde4
CR7961A (es) Compuestos de aminoheteroarilo como inhibidores de las proteinquinasas
CR9238A (es) Pirrolopirazoles, potentes inhibidores de cinasa

Legal Events

Date Code Title Description
FG Grant of patent